Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

PaperCitations, authors & open-access status

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 65 citations, 2025 year and closed oa status.

65
Citations
2025
Year
closed
OA Status

Related on ScholarIQ

W A Macdonald
Author
The Lancet Oncology
Journal
Prostate Cancer Treatment and Research
Topic
Prostate Cancer Treatment and Research
Topic
Prostate Cancer Diagnosis and Treatment
Topic
Radiopharmaceutical Chemistry and Applications
Topic
470M+ articles · free account